Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Price

CTNMStock
$17.05+67.30%52W
Market Cap$641.44M
P/E
PEG Ratio
Div yield
Beta-0.03

CTNM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-1.98%
Price vs S&P 500 (4W)14.39%
VGM Score79.84

CTNM Earnings Surprise History

Q2 25-0.62est. -0.41
Q3 25-0.45est. -0.46
Q4 25-0.49est. -0.39
Q1 26-0.39est. -0.53
Q2 26-0.40est. -0.45

CTNM Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.31
4.31
4.31
4.29

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CTNMContineum Therapeutics, Inc. Class A Common Stock
B$17.05
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for serious diseases with high unmet need. The company's pipeline includes PIPE-791, a brain-penetrant LPA1 receptor inhibitor in development for idiopathic pulmonary fibrosis, and PIPE-307, a muscarinic M1 receptor inhibitor for depression and relapsing-remitting multiple sclerosis.